Umbilical Cord Blood Cell
What are cord blood cells ?
Umbilical cord blood (UCB), once regarded as biological waste, has become an accepted source of hematopoietic stem cells/hematopoietic progenitor cells (HSCs/HPCs), similar to those found in bone marrow and peripheral blood. These cells can be used to replenish a patient’s immune system by providing stem cells for transplantation, just as bone marrow or peripheral blood stem cell transplants can be used to treat malignant diseases such as leukemia and non-malignant diseases such as immune deficiencies and severe aplastic anemia, and congenital disorders such as sickle cell anemia and thalassemia.
UCB contains many types of blood cells but only the hematopoietic — or blood-making — stem cells in the UCB are currently useful for transplant. Other uses of UCB stem cells are currently undergoing research. Each source of HPCs (bone marrow, peripheral blood or cord blood) has advantages and disadvantages associated with its use in a transplant. Decisions about the most appropriate source of stem cells — which must be matched by tissue type to some degree with the recipient — must be made by each patient in consultation with his or her physician based on available
Clinical Evidence
The safety of any medical treatment is best assessed through rigorous clinical trials and scientific research. Since 2009, numerous clinical trials have explored the safety of umbilical cord-derived stem cell therapy, providing valuable insights into its potential risks and benefits.
While most of the existing clinical research has been on smaller numbers of patients receiving therapy, the lack of reported adverse events from UC-MSC transplantations is encouraging. A review of peer-reviewed studies on UC-MSCs on 2001 patients with 53 different illnesses showed that no tumor formation, cell rejection, or long-term adverse events were reported.
One study followed up after 6 years on nine patients that received UC-MSC transplantations for Lupus. No adverse events aside from one patient having transient discomfort when first receiving the therapy were reported. No tumor markers were elevated, and no new-onset abnormalities were found on electrocardiogram or chest radiography. Though larger long-term studies are warranted, this supports our understanding of a good safety profile for the clinical use of UC-MSCs.
Trusted
1. Our lab is registered and regulated by the Food and Drug Administration (FDA).
2. Follows the highest standards established for cord blood banking.
- 1. National Marrow Donor Program® (NMDP)
- 2. World Marrow Donor Association® (WMDA)
- 3. Association for the Advancement of Blood & Biotherapies (AABB)
- 3. Licensed in all states that require a license.
- 4 .Approved for collections in all 50 US states.
Safer Transplants
1. We have released over 2,200 units
for transplant, research and clinical trials.
2.Fewer red blood cells means, safer transplants.
3. Our process removes 98.5% ofthe red blood cells
versus 33.45% by ourcompetitors.
More Stem Cells
1. Our proprietary processrecovers.
2. About 35% more stem cells than our
competitors.
Results
1. Our product(s) have been successfully trans
planted in thousands of patients through clinical trials, and for therapies.
2. Existing distribution channels for therapies and clinical research have yielded success.
3. Clinical accomplishments and advocacy led by leading surgeons and clinics.
4. Our process excels in clonogenic potential, resulting in superior therapeutic outcomes.
5. CFL productrecovers more T Cells,
B Cells, and HSCs.
Our Processing System
Our processing system is used to isolate the greatest amount of stem cells from umbilical cord blood.
1. The process is the most flexible cord-blood processing method, offering several special benefits and advantages over other processing methods.
2. The end result includes a reduction in the time to neutrophil engraftment.
3. It yields the highest number of colony-forming units (CFUs), which is currently the most accurate measurement to determine stem cell potency and the potential for stem cell engraftment.
4.It recovers the greatest percentage of CD34+ stem cells from human umbilical cord blood.
5. This processing type ensures that TNC and CD 34+ recovery is not affected by the initial volume of the collected unit.
6. It provides the greatest reduction in red blood cell (RBC) contamination compared with all other processing methods.
7. Processed samples have a significantly greater clonogenic potential than all current methods.
CTD Processing System
Better Treatment Outcomes
1. The result of the differences between processing methods has been shown to lead to better treatment outcomes.
2. With this processing method, processed cord blood units engraft more quickly than any other methods.
3. In an evaluation of the probability of and the time to patient neutrophil recovery by the St. Louis Cord Blood Bank, this processing had a median time of 16 days compared with 20 days for the Hespan group.
4. "After infusion of a single HES unit, 89% of patients achieved engraftment in 23 days (median 20). … After receiving a single processed unit, 91% of patients achieved engraftment in 18.6 days (median 16)."
5. Additionally, when the data on engraftment times from a number of public data sources were compared, this processing was found to engraft more quickly than all other cord blood–processing methods.
STABILITY EFFICACY PURITY
Why Our Products are superior?
Our unique process recovers about 35% more stem
cells and removes 98.5% of the red blood cells
compared to other company's methods that remove
around 70% red blood cells.
Due to our unique processing method, we do not
have to lyse the 30% red bloods cells like other
companies. Lysing the red blood cells leaves debris
that may cause harm to patient when doses are
administered. Lysing also damages the live cells
making the final product less effective.
Some processors add solutions like saline or a Red
Blood Cells Lysis Buffer to make the product look
pinkish. By using such products, they damage the
live cells making the product less effective.
Understanding Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)
Wharton’s Jelly is a gelatinous substance found within the umbilical cord. It contains a rich source of mesenchymal stem cells (MSCs), which are versatile cells capable of differentiating into various cell types in the body. This unique characteristic has led to their potential use in treating a wide range of conditions, from orthopedic issues to autoimmune disorders.
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are readily accessible, being collected from healthy donors post-delivery. This process avoids ethical controversies and poses no risk to either the mother or the child.
Consideration For Patients
1. Consulting with Healthcare Professional
Before undergoing any stem cell therapy, it is imperative to consult with a qualified healthcare professional, especially one experienced in regenerative medicine procedures such as UC-MSC therapies. They can assess your medical history, discuss treatment options, and provide personalized recommendations based on your symptoms and conditions.
2. Evidence-based Decisions
Use clinical research and scientific data to inform your decisions. Consider pursuing medical interventions that have undergone thorough examination and that are supported by well designed, peer-reviewed medical literature.
3. Realistic Expectations
While umbilical cord-derived stem cell therapy holds immense potential, it’s important to maintain realistic expectations. Not all conditions respond equally to this treatment, and outcomes may vary from person to person.
4. Monitoring and Follow-up
After receiving stem cell therapy, you should expect regular follow-up with your healthcare provider. At AIRCR, we monitor your progress regularly. This allows us to address any concerns promptly. This may contribute to safer and more successful treatment outcomes.